>
Testing brain tissue for plaques and tangles is the only definitive way to diagnose Alzheimer’s disease. This is done during a brain autopsy after someone dies. While a person is still living, doctors are only able to make a diagnosis of “possible” or “probable” Alzheimer’s disease and this requires a full physical and neurological examination to rule out other causes of dementia. Screenings include blood tests to measure thyroid function and vitamin B12 levels, an MRI or CT scan of the brain to exclude other causes of dementia such as strokes, tumors, or hydrocephalus (excessive fluid build-up in the brain), and cognitive testing for memory, language, and other cognitive difficulties.
There is no medical treatment currently available to cure or stop the progression of Alzheimer's disease. However, the Food & Drug Administration (FDA) has approved four drugs that may temporarily relieve some symptoms of the disease or slow its progression. These are tacrine (Cognex®), donepezil (Aricept®), rivastigmine (Exelon®), and galantamine (Reminyl®). Many other new promising drugs are now being developed - some of which may be available within the next few years. Medication and non-drug therapies are also available to reduce some of the changes in behavior associated with Alzheimer's disease, such as depression, sleeplessness, and agitation.
Generally, donepezil (Aricept®), rivastigmine (Exelon®), and galantamine (Reminyl®) are well tolerated. Symptoms such as nausea, vomiting, loss of appetite, and loose stools might occur but are usually transient. It is recommended to take Reminyl® and Exelon®with a full meal. Because of side effects associated with tacrine, including possible liver damage, it is very rarely prescribed. There is no evidence or reason to believe that combining the drugs would be any more beneficial than taking either one alone, and it is likely that combining the drugs would result in greater side effects.
Diagnosing and treating Alzheimer's Disease involves a combination of medical assessments, cognitive evaluations, and supportive care. Here's an overview of the diagnosis and treatment of Alzheimer's Disease:
Diagnosis:
Treatment: It's important to note while there is no cure for Alzheimer's Disease, several treatments and interventions can help manage symptoms and improve the quality of life for individuals with the condition:
The specific treatment plan for Alzheimer's Disease may vary depending on the individual's symptoms, stage of the disease, and other factors. It is essential for individuals and their families to work closely with healthcare professionals to develop a personalized care plan. Early diagnosis and intervention are key to maximizing the effectiveness of treatment and support.
Jody Hiltz has been Clinical Administrative Assistant for Dr. Marks since 2017. She received her Associate of Science Degree from Quincy College. Your can find her smiling face greeting you when you enter our office.
Liz has been working for the practice for over 3 years. Prior to that she worked in skilled nursing facilities as a Life Enrichment Director/Dementia Practitioner. She loves supporting patients and their caregivers. Our practice offers expert level care in a community setting. Because of our association with an international research corporation we are also in a unique position to extend opportunities for treatments not otherwise available. She believes that it’s a pleasure to be a part of staff here who works as a team to provide education, support and as much as possible, a bit of amusement. Her goal is to help our patients maintain their independence and quality of life for as long as possible.
Years ago her grandfather was diagnosed with Alzheimer’s Disease then after taking care of her father her mother was diagnosed. She has worked in the medical field for over four decades as a Medical Biller but finds herself so fortunate to be working for this neurology practice as a Clinical Administrative Assistant in more of a “face to face” capacity with our patients. The years of experience supporting her mother through the disease was an education in what it takes to be a caregiver. She feels she developed more insight into what we can provide here to aid our patients and their support group. She feels she is especially blessed to be in an environment locally that can offer research trials that would not otherwise be accessible. She loves that the team here works to provide smiles every day to the ‘family’ that walks through our doors.
Morgan Tromblee has been working in Alzheimer’s disease research as a sub-investigator with Dr. Donald Marks since 2022. She also works clinically in the outpatient neurology setting, primarily seeing patients with Alzheimer’s and Parkinson’s disease. She received her master’s at the MGH Institute of Health Professions Physician Assistant Program, and her bachelor’s in biology at the University of Vermont.
Elizabeth Simpson has been working in Alzheimer’s disease research as a sub-investigator with Dr. Donald Marks since 2021. She also works clinically in the outpatient neurology setting, primarily seeing patients with Alzheimer’s and Parkinson’s disease. Lizzy received her master’s degree in medical science at the Tufts University Physician Assistant Program, and her bachelor’s degrees at Providence College.
Dr. Hreib obtained his MD, Ph.D. and M.B.A. From Boston University and was trained in medicine and Neurology at Boston University Medical Center and Boston City Hospital. His professional life as a neurologist began at Lahey Clinic in Burlington, MA, where he was the director of Vascular Neurology for over twenty years, after which he became the chief of Neurology at Mount Auburn Hospital in Cambridge, MA before becoming the Chief Medical Officer for Baystate Health North. Dr. Hreib continued to see patients as a neurologist while the chief medical executive and later decided to join Donald Marks clinic on neurodegenerative disease in Plymouth.
For over 30 years, Dr. Marks has focused on the treatment of neurodegenerative diseases, specifically in the areas of Alzheimer’s and Parkinson’s disease. Dr. Marks has been the Principal Investigator (PI) in over 40 clinical trials with numerous pharmaceutical and imaging companies as well as with the National Institutes of Health (NIH). Dr. Marks is a member of the medical staff at the Beth Israel Lahey Health Hospital (BILH) Plymouth and the Nantucket Cottage Hospital. He is the founding Medical Director for the Division of Neurology at the BILH Plymouth.